AngioDynamics has entered an agreement to acquire RadiaDyne for an undisclosed sum.
The transaction will add RadiaDyne’s OARtrac® device and IsoLoc/ImmobiLoc technology to AngioDynamics’ product portfolio.
OARtrac® is a radiation dose monitoring platform designed to provide accurate measurement of radiation doses, while IsoLoc/ImmobiLoc is an endo-rectal technology that removes transient rectal gas using a patented gas-release tip.
AngioDynamics is engaged in the design and manufacture of medical, surgical and diagnostic devices for use in oncology, while RadiaDyne is a provider of surgical and other medical diagnostic instruments. Both parties are based in the US.
The acquisition will expand AngioDynamics’ oncology product portfolio.
Johnson & Johnson Medical has completed the acquisition of Emerging Implant Technologies (EIT) for an undisclosed sum.
The acquisition will be a complementary addition to J&J’s US-based orthopaedics business unit DePuy Synthes’ interbody implant segment for minimally invasive and open spinal fusion surgery. It will strengthen DePuy’s global offering of interbody spine implants pipeline.
Based in the UK, J&J Medical is a medical device company that manufactures intravenous catheters, wound and skin care products, and surgical packs, while EIT is a spinal implant cages manufacturer based in Germany.
Stryker has agreed to purchase Invuity for a cash consideration of $190m or for $7.40 a share of common stock.
Invuity will be merged with the business of a subsidiary of Stryker after the completion of the transaction.
The deal is expected to close in the last quarter of 2018, subject to customary closing conditions and other regulatory approvals.
Stryker is a provider of specialty surgical and medical products, while Invuity is a developer of surgical devices. Both are based in the US.
The transaction will enable Stryker to achieve better patient outcomes and operating room efficiencies in women’s health, general surgery, and orthopaedics.